托法西替尼在耐固醇性急性严重性结肠炎中的实用性
Mukesh K Ranjan1, Pradeep Neupane1, Bigyan Maharjan1
1Gastroenterology and Hepatology, Chitwan Medical College and Teaching Hospital, Bharatpur, NPL.
Cureus
|November 15, 2024
概括
托法西替尼 (tofacitinib) 是一种有前途的急性严重性结肠炎 (ASUC) 救援疗法,用于耐固醇患者. 四分之三的患者实现了缓解,避免了胆管切除和类固醇依赖.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性严重性结肠炎 (ASUC) 带来了重大治疗挑战.
- 托法西提尼布是ASUC中救援治疗的新兴选择.
- 类固醇耐火性ASUC通常需要先进的治疗策略.
研究的目的:
- 评估托法西提尼布作为救援疗法的疗效和安全性,以治疗类固醇耐药ASUC.
- 报告一小群未使用生物制剂的ASUC患者用tofacitinib治疗的结果.
主要方法:
- 回顾四名患有类固醇耐药ASUC的患者病例系列.
- 患者接受了托法西提尼布治疗,开始服用10毫克每天三次或每天两次.
- 评估的结果包括临床缓解,胆管切除率和不良事件.
主要成果:
- 四分之三 (75%) 的未使用生物药物的患者实现了临床缓解.
- 在随访期间,这三名患者仍然没有进行胆管切除术,也没有使用类固醇.
- 一名患者对托法西提尼布无反应,随后需要进行大肠切除术.
结论:
- 托法西替尼在这种小群体的类固醇耐药ASUC患者中显示出令人鼓舞的成功率作为救援疗法.
- 治疗耐受性良好,没有观察到与托法西替尼相关的不良事件.
- 需要进一步的研究来证实这些发现在更大的ASUC种群中.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
96
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Inflammatory Bowel Disease IV: Pharmacological Management
114
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
114
Inflammatory Bowel Disease V: Surgical Management
122
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
122


